We have investigated the influence of a novel angiotensin II type 1 receptor antagonist, candesartan cilexetil, on the oxidative state of renal tissue and renal function in 5/6 nephrectomized rats, and compared its effects with those of an angiotensin-converting enzyme inhibitor, enalapril. Candesartan cilexetil (1 and 5 mg/kg per day), enalapril (5 mg/kg per day) and vehicle were orally administered once daily for 16 weeks after 5/6 nephrectomy. There was a marked degree of proteinuria evident prior to treatment, an average of 5.69 mg/mg creatinine in the nephrectomized rats, vs 1 to 2 mg/mg creatinine in the control group matched for species and body weight. Inhibition of development of proteinuria by candesartan cilexetil was dose dependent. Enalapril also significantly blunted the rise in urinary protein. Malondialdehyde content in the homogenate from the renal cor-
Introduction
Angiotensin-converting enzyme (ACE) inhibitors appear to delay the progression of diabetic 1 and nondiabetic 2,3 renal diseases. It has been suggested that glomerular hypertension is a primary factor responsible for the development of progressive glomerular injury in experimental models. Studies in animals with type 1 diabetes mellitus have suggested that ACE inhibitors could reduce glomerular damage by reduction in glomerular capillary pressure. 4 , 5 The beneficial influences of ACE inhibitors on renal function may be independent of the effects on systemic blood pressure. 4, 5 Findings in experimental models suggest that ACE inhibitors may exert renoprotective effects through haemodynamic as well as non-haemodynamic mechanisms. In obese Zuker rats, an animal model with type II diabetes, administration of an ACE inhibitor reduced glomerular injury, while causing little change in glomerular capillary pressure. 6 In addition, the possibility that effects of ACE inhibitors might be associated with non-haemodynamic changes was provided by stud- ies in a model of persistent nephrotic syndrome induced by puromycin. 7 Severe reductions of renal mass lead to morphologic and functional alterations, with marked increases in the perfusion and filtration of the remaining nephron unit. Increases in plasma flow rate and glomerular transcapillary hydraulic pressure gradient cause glomerular hyperfiltration. 8 Glomerular hyperfiltration is associated with progressive proteinuria and glomerular sclerosis. 8 It has been suggested that oxidative stress markedly increases in the residual renal tissues of subtotal nephrectomized rats, 9 and may also be involved in the progression of renal injury in this experimental model. 10 In subtotal nephrectomized rats, angiotensin II type 1 receptor (AT 1 ) antagonists have beneficial effects on progressive renal deterioration, probably through glomerular haemodynamic alteration in the residual kidney. 11, 12 However, it remains unclear whether AT 1 antagonists ameliorate residual renal tissue injury through the suppression of hyperoxidative state. To address this issue, rats with a 5/6 reduction in renal mass were given long-term treatment with the newly developed AT 1 antagonist, candesartan cilexetil or an ACE inhibitor, enalapril. The effects of these agents on systemic blood pressure, urinary protein excretion, antioxidative enzyme activity, and lipid peroxidation of the remnant kid-S64 ney, as well as on microscopic structure of the tissues, were examined.
Materials and methods

Animals
Male 6-week-old Wistar rats (Japan SLC, Shizuoka, Japan) were subjected to 5/6 nephrectomy. Under pentobarbital anesthesia (50 mg/kg, intraperitoneal), renal ablation was achieved by ligation of the renal artery branches supplying two-thirds of the left kidney, followed 7 days later by a right unilateral nephrectomy. Six weeks later, the 5/6 nephrectomized rats were divided into four groups; group I (n = 10) received vehicle (0.5% methyl cellulose solution) alone, group II (n = 10) and group III (n = 9) were given candesartan cilexetil at 1 and 5 mg/kg per day, respectively, group IV (n = 10) was treated with 5 mg/kg per day of enalapril. The compounds, dissolved in 0.5% methyl cellulose solution, were administered by gastric gavage once daily for 16 weeks. The doses of candesartan cilexetil (1 mg/kg) and enalapril (5 mg/kg) were chosen on the basis of an equipotent suppression in pressor responses against intravenous injection of angiotensin I to rats (data not shown). Candesartan cilexetil was donated by Takeda Chemical Industries (Osaka, Japan). Enalapril maleate was obtained from Sigma Chemical (St Louis, MO, USA).
All rats were housed two per cage, fed standard chow (CA-1; Japan Clea, Tokyo, Japan) and allowed free access to water. Untreated rats matched for species and body weight were used as controls.
Blood pressure, urine protein excretion, and endogenous creatinine clearance were obtained before and during the treatment period biweekly, except in control rats. Blood samples for serum creatinine were obtained from the tail vein after the urine collection. At the end of the treatment period, the abdominal aorta was catheterized with PE-90 tubing under pentobarbital anaesthesia (50 mg/kg, intraperitoneal) and blood was collected. The kidney was then thoroughly perfused with cold phosphate buffered saline (pH 7.4), excised, the capsule and surrounding fat and scar were removed, and the weight was recorded. The kidney tissue was carefully divided in ice-cold phosphate buffered saline into cortex and medulla, then the tissue was snap frozen in liquid nitrogen and stored at −80°C. A portion of perfused kidney was used for histologic examination.
The experiment was conducted in accordance with the Jichi Medical School Guide for Laboratory Animals.
Blood pressure measurement and urine collection
Blood pressure was determined in awake, prewarmed rats by a standard tail-cuff method (KN-210-1, Natsume, Tokyo, Japan). At least 15 determinations were made and the consecutive lowest three measurements were averaged to obtain a mean systolic blood pressure measurement for each rat.
To determine protein excretion and creatinine clearance, a 4-h urine was collected in metabolic cages after water loading (3% of body weight) by gastric gavage. Urine protein excretion was normalised in terms of urine creatinine concentration.
Serum and urine chemistries
Albumin, cholesterol, and triglycerides were measured in serum, and creatinine was measured in both serum and urine, using an autoanalyser (Hitachi 7170, Hitachi, Tokyo, Japan). Urinary protein concentration was measured by a pyrogallol-red molybdate complex method. 13 Concentrations of urinary N-acetyl-␤-D-glucosaminidase (NAG) were determined by a colorimetric assay.
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Assessment of antioxidative status
Measurement of glutathione peroxidase (GSH-Px) activity:
The kidney tissues were homogenised with 10 vol of 120 mmol/L KCI and 30 mmol/L potassium phosphate, pH 7.4, and centrifuged at 200 000 g for 20 min. The supernatant was assayed for GSH-Px activity by oxidization of reduced nicotinamide adenine dinucleotide phosphate (NADPH) to nicotinamide adenine dinucleotide phosphate (NADP) with a molar extinction coefficient for NADPH at 340 nm of 6.22 × 10 6 per min. 
Measurement of superoxide dismutase (SOD) activity:
The supernatant was assayed for total superoxide dismutase (SOD) (Cu, Zn-SOD plus Mn-SOD) activity by following the inhibition of nitroblue tetrazolium (NBT) reduction by superoxide anion at 560 nm. 16 One unit of SOD was defined as the amount of enzyme necessary to cause a 50% inhibition of the reduction of NBT (0.24 mmol/L) by superoxide anion generated by the xanthine (0.4 mmol/L)-xanthine oxidase (0.049 U/mL) system. Commercially available Cu, Zn-SOD (Wako Pure Chemicals, Osaka, Japan) was used as a standard. 
Measurement of catalase activity:
Determination of lipid peroxidation by measurement of thiobarbituric acid-reactive substance (TBARS)
The tissue homogenate was centrifuged at 600 g for 10 min, and the supernatant was used for TBARS determinations. Lipid peroxides were measured as malondialdehyde (MDA), produced by acid heating using its reaction to thiobarbituric acid (TBA). 18 A mixture of 0.1 mL of the supernatant, 0.1 mL 8.1% sodium dodecyl sulfate, 10 L 2% butylated hydroxytoluene in ethanol, 0.75 mL 20% acetic acid, 0.3 mL 1/3 mmol/L FeCl 3 and 0.75 mL 0.8% TBA was boiled at a temperature more than 95°C for 30 min. After adding 0.5 mL deionized water and 2.5 mL n-butanol/pyridine (15:1, v/v), the mixture was vigorously shaken and centrifuged at 1,500 g for 10 min. The absorbance of the upper organic layer was measured at 532 nm. 1,1,3,3-tetramethoxypropane was used as an external standard.
Histologic examination
Renal tissues were fixed in 20% neutral formalin solution, embedded in paraffin, and cut into thin sections using conventional techniques. The sections were stained with haematoxylin-eosin and periodic acid Schiff's reagent (PAS).
Statistical analysis
Results are expressed as means ± s.e. The statistical significance of differences between group means was tested by one-and two-way ANOVA, and post hoc tests (Scheffe's multiple comparison test) as appropriate. Statistical difference was considered significant at P value less than 0.05.
Results
Blood pressure
The 5/6 nephrectomized rats treated with vehicle remained mildly hypertensive during the study period. Treatment with candesartan cilexetil at a dose of 1 mg/kg per day significantly lowered systolic blood pressure and the 5 mg/kg per day dose normalised this variable. Enalapril at a dose of 5 mg/kg per day significantly decreased systolic blood pressure at a comparable level in rats treated with candesartan cilexetil given at a dose of 1 mg/kg per day (Figure 1 ).
Renal function
In this study, urine protein excretion was quantified by urine protein/creatinine ratio in the 4-h urine after water loading. The ratio in control rats was below 2 mg/mg creatinine. An elevation in urinary protein excretion and the development of pro- teinuria were evident in rats with the 5/6 nephrectomy ( Figure 2 ). Candesartan cilexetil attenuated the development of proteinuria in a dose-dependent manner. Enalapril also significantly blunted the development of proteinuria. At the end of the 16-week treatment period, the agents significantly decreased proteinuria without statistically significant differences among the drug-treated groups.
Creatinine clearance at 6 weeks after 5/6 nephrectomy was similar to that of control rats. During the treatment period, creatinine clearance declined mildly but significantly, whereas its changes were unaffected by candesartan cilexetil or enalapril administration (Figure 3) .
Urinary NAG excretion after 16 weeks of administration was higher in the vehicle-treated than in the control rats. High-dose candesartan cilexetil and enalapril normalised urinary NAG excretion. Candesartan cilexetil dosed at 1 mg/kg per day did not influence urinary NAG excretion. 
Kidney weight
Mean kidney weight was 2.00 ± 0.07 g in the vehicle-treated group, 2.03 ± 0.08 g in the lowerdose candesartan cilexetil-treated group, 1.77 ± 0.07 g in the higher-dose candesartan cilexetil-treated group, and 1.66 ± 0.06 g in the enalapriltreated groups. Normalised for body weight, the wet weight of the kidney per kilogram of body weight in rats treated with the higher dose of candesartan cilexetil or enalapril was significantly lower compared to that of the vehicle-treated rats (Figure 4) . At the end of the treatment, body weight was not significantly different among groups.
Serum chemistries
The decrease in serum albumin was dose-dependently suppressed by candesartan cilexetil. Enalapril also prevented slightly, but insignificantly, the decrease in serum albumin. The increases in serum cholesterol and triglyceride were significantly inhibited by the higher dose of candesartan cilexetil and enalapril (Table 1) .
Antioxidative enzyme activities
In addition to measuring different antioxidative enzyme activities, the amount of lipid peroxidation was determined by evaluating renal tissue TBARS content (Table 2) . TBARS in homogenate from the renal cortex increased significantly in the 5/6 nephrectomized rats as compared to control animals. Candesartan cilexetil or enalapril did not affect the elevation of TBARS content in the renal cortex tissue. GSH-Px activity in the renal cortex tissue was significantly lower in the nephrectomized rats with vehicle and the lower-dose candesartan cilexetil. Total SOD activity was not altered by any active treatment. Catalase activity tended to decrease in the vehicle-treated rats, and the activity was not affected by the agents.
In renal medulla tissue, TBARS content insignificantly increased in the 5/6 nephrectomized rats without influence of an agent. GSH-Px and total SOD activities tended to decrease in the nephrectomized rats. Candesartan cilexetil or enalapril did not affect the antioxidative enzyme activities in the renal medulla tissue. Catalase activity in the nephrectomized rats was near control levels.
Histologic findings
The nephrectomized rats treated with vehicle showed moderate glomerular sclerosis ( Figure 5A ). Degenerative changes in tubules and interstitial mononuclear cell infiltration were also noted in the vehicle-treated rats. Candesartan cilexetil and enalapril significantly suppressed the glomerulosclerosis. Both the lower dose of candesartan cilexetil and enalapril reduced similarly the sclerotic changes in the glomeruli ( Figures 5B and 5C , respectively). The higher dose of candesartan cilexetil further ameliorated the glomerulosclerosis ( Figure 5D ). Histopathologic changes in tubules and interstitial mononuclear cell infiltration were also prevented by administration of the agents.
Discussion
The results of the present study demonstrated that the AT 1 antagonist, candesartan cilexetil, improved the development of proteinuria and ameliorated glomerular sclerosis in the 5/6 nephrectomized rats. In this study, we addressed the involvement of antioxidative properties of candesartan cilexetil in the renoprotective effect. Lipid peroxide content, determined as MDA, was increased in renal cortex homogenate from the nephrectomized rats. The elevated lipid peroxide content, however, was not influenced by the treatment with either candesartan cilexetil or enalapril. Based on these findings, we think that antioxidative effects of these agents are small, if any. In the vehicle-treated nephrectomized rats, antioxidative enzyme activities such as GSHPx and catalase were lower than those of control rats. These results indicate that oxidative stress in renal tissue is enhanced in the remnant renal tissue and that the decreased antioxidative enzyme activities may partly be involved in the enhanced oxidative stress.
Creatinine clearance before treatment was similar to that in intact control rats, indicating that the animals at 6 weeks after subtotal nephrectomy were in S67 a state of glomerular hyperfiltration. Enalapril ameliorated renal function in 5/6 remnant kidney model associated with a reduction in glomerular capillary hydraulic pressure. 19 During the treatment period, whole kidney glomerular filtration rate (GFR) as determined by creatinine clearance, fell to a small but significant degree without significant influence by any treatment. One of the explanations for this phenomenon is further elevation of the single nephron plasma flow and filtration rates despite loss of remaining functional nephrons. Candesartan cilexetil 11 and enalapril 19 have been shown to normalise glomerular capillary hydraulic pressure without significant reduction in single-nephron GFR in 5/6 nephrectomized rats. These findings explain, in part, the present results that creatinine clearance was unaffected by candesartan cilexetil or enalapril.
It has been proposed that free radicals participate in the pathogenesis of progressive renal injury. 20 In remnant renal tissue of nephrectomized rats, oxygen consumption per remaining nephron is increased, which, in turn, induces an overproduction of reactive oxygen species in the remnant kidney. 9, 10, 21 An imbalance of reactive oxygen species production and scavenging by antioxidative enzymes exerts oxidative stress in the remnant kidney, resulting in renal injury. Supplement of free radical scavenger has shown to protect against renal injury, 22 while dietary depletion of antioxidants promotes renal injury. 23 It has been suggested that ACE inhibitors protect tissues from oxidative damage by increasing antioxidative defences, including the free radical scavenging effect. 24 In this study, the reduced antioxidative enzyme activities in renal cortex homogenate, such as GSH-Px and catalase, were not significantly affected by any of the drugs. Therefore, our results suggest that the reduction of oxidative stress in residual renal tissue may not be involved in renal protective effect of candesartan cilexetil and enalapril in nephrectomized rats.
Our results are consistent with those of recent studies in which candesartan cilexetil confers beneficial effects on renal function in various experimental models, including rats with reduced renal mass. [25] [26] [27] [28] [29] During the treatment period, the vehicletreated rats maintained mild hypertension without further blood pressure rise, while proteinuria developed progressively. Both the lower-dose candesartan cilexetil and enalapril lowered blood pressure to a similar level. The higher-dose candesartan cilexetil further reduced the blood pressure. Proteinuria was attenuated by candesartan cilexetil and enalapril, similar to the blood pressure-lowering effect. Both the higher-dose candesartan cilexetil and enalapril normalised urinary NAG excretion, suggesting these agents prevented the development of tubular injury. Histopathologic findings revealed similar degrees of the improvement of glomerulosclerosis in rats treated with candesartan cilexetil at the lower dose, and those treated with enalapril. There appear to be no major differences in the renoprotective effects between candesartan cilexetil and enalapril.
Hypertrophy of the residual kidney develops after partial nephrectomy. Candesartan cilexetil decreased the kidney-to-body weight ratios dose dependently. Enalapril further reduced the residual renal mass, although its renoprotective effect was similar to that of the lower-dose candesartan cilexetil. ACE inhibitors and AT 1 antagonists suppress AT 1 -mediated responses such as direct stimulation of cell proliferation and growth, and induction of expression of vasoactive substances and cytokines, which lead to increased production of extracellular matrix components. 30 In addition, AT 1 antagonists increase angiotensin II, angiotensin (1-7) and angio-
